Assembly Biosciences Director Jeanine W. Ajaka Departs Board

Assembly Biosciences Inc. disclosed that Jeanine W. Ajaka resigned as a member of the company's board of directors effective June 4 2026 according to an 8-K filed with the SEC on June 5 2026.

The filing lists Item 5.02 Departure of Directors or Certain Officers. Ajaka served as an independent director. The company stated that her resignation was not the result of any disagreement with the company on any matter relating to the company's operations policies or practices. No successor has been named.

The departure reduces the number of directors serving on the board. Prior to the change the company maintained a board whose composition satisfied Nasdaq independent-director and committee requirements. The new board size takes effect immediately on June 4 2026.

The company must update its governance disclosures and may need to adjust committee assignments to maintain compliance with Nasdaq listing standards and SEC rules on board composition.

Downstream the resignation obliges Assembly Biosciences to file any additional disclosures required under Item 5.02 within the four-business-day window already met by the June 5 filing. The company will also update its proxy statement and any future Form 10-K or 10-Q filings to reflect the revised board membership.

If the board falls below the minimum number of independent directors Nasdaq rules require prompt remediation usually within 180 days or the company must explain its plan to regain compliance. The change also affects the pool of directors eligible to serve on the audit compensation and nominating committees triggering immediate internal review of committee rosters.

This marks the latest board-level change at the clinical-stage biotechnology company which has maintained a stable independent-director roster in recent years while advancing its virology-focused pipeline. The 8-K also reported results of matters submitted to a vote of security holders at the annual meeting and included related exhibits.